Skip to main content
. 2019 Jan 18;20(2):412. doi: 10.3390/ijms20020412

Table 2.

FDA-approved PI3K inhibitors.

Therapeutic Drug Target (s) Clinical Trial Status Developer
Idelalisib (CAL101) PI3Kδ inhibitor FDA Approved Gilead Sciences
Copanlisib Pan-class I PI3K inhibitor FDA Approved Aliqopa; Bayer
Duvelisib (ABBV-954, INK-1197, IPI-145) PI3Kδ/PI3Kγ inhibitor FDA Approved Copiktra; Verastem